<
AI
Automation
Science
Innovation
Open Source
Blockchain
Social Media
Startups
Culture
Cloud
>

Destination
Here's how much Ozempic and similar drugs have soared in popularity since 2018

The use of GLP-1 meds — made popular by Ozempic (NVO) — among U.S. adults without diabetes more than tripled between 2018 and 2022, with annual spending surging from $1.6 billion to $5.8 billion.Read more... [...]

Discover Copy
Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
Engadget Podcast: iPhone 16e review and Amazon's AI-powered Alexa+

The keyword for the iPhone 16e seems to be "compromise." In this episode, Devindra chats with Cherlynn about her iPhone 16e review and try to figure out who this phone is actually for. Also, [...]

Match Score: 76.63

thenextweb
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy

London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biot [...]

Match Score: 64.73

Destination
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]

Match Score: 58.94

Destination
Google's most powerful AI tools aren't for us

At I/O 2025, nothing Google showed off felt new. Instead, we got a retread of the company's familiar obsession with its own AI prowess. For the better part of two hours, Google spent playing up p [...]

Match Score: 50.69

blogspot
How I Get Free Traffic from ChatGPT in 2025 (AIO vs SEO)

Three weeks ago, I tested something that completely changed how I think about organic traffic. I opened ChatGPT and asked a simple question: "What's the best course on building SaaS with Wor [...]

Match Score: 50.29

Destination
All the tech and gadgets announced at CES 2026

It's the first week of a new year and there's no time for the tech world to slowly ease back into things following the holidays. That's because CES 2026 is in full swing, with all manne [...]

Match Score: 44.44

Destination
iPhone 17 Pro and Pro Max review: An impactful redesign

For the sake of this iPhone 17 Pro review, I’ve developed a gaming addiction. <br /> I don’t mean triple-A games like Destiny: Rising and Genshin Impact, or even double-A or non-A titles lik [...]

Match Score: 43.10

Destination
Norton VPN review: A VPN that fails to meet Norton's standards

One thing I need to make clear right from the start: this is a review of Norton VPN (formerly Norton Secure VPN, and briefly Norton Ultra VPN) as a standalone app, not of the VPN feature in the Norton [...]

Match Score: 43.03

Destination
Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup

Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that it has begun two late-stage clinical tr [...]

Match Score: 42.10